The Effect of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on the Lipid Profile of Diabetic Patients Using Statins: A Retrospective Cohort Study in the Diabetic Center of King Salman Bin Abdulaziz Hospital, Saudi Arabia.

Albahli OM, Ali S, Alblaihi F, Aljaman AA

Cureus27 Jul 2024Cited by 3 (Europe PMC)

PMID39188504PMCIDPMC11346815DOI10.7759/cureus.65521PepBankPUB-39188504

Summary

Background Dyslipidemia is a common complication of type 2 diabetes mellitus (T2DM), which is the leading cause of morbidity and mortality in developed countries, including Saudi Arabia. Injectable glucagon-like peptide-1 receptor agonists (GLP-1RA) are recent therapies found to be effective in treating dyslipidemia in diabetic patients by acting similarly to the body's internal glucagon peptide hormone, regulating blood sugar levels and reducing triglycerides and low-density lipoprotein (LDL) levels. Aim of the study This retrospective cohort study aimed to investigate the effect of GLP-1RA on the lipid profile of dyslipidemia diabetic patients who were not controlled using statins. Methods Data were collected from the medical records of male and female diabetic patients with dyslipidemia (uncontrolled by statins) who were administered to the diabetic center of King Salman Bin Abdulaziz Hospital in Riyadh, Saudi Arabia, and received GLP-1RA (dulaglutide) from June 2023 to August 2023. The primary endpoint was the change in triglycerides and LDL-C levels after three months of using dulaglutide, and the secondary endpoints included the change in body weight, BMI, and HbA1c%. Descriptive analysis was conducted to present numerical and categorical data. The Wilcoxon signed-rank test was used to compare numerical data before and after using dulaglutide. Ethical considerations were taken into account by ensuring anonymous data collection and obtaining IRB approval before data collection. Results The study included 102 patients with a median (interquartile range (IQR)) age of 59 (14) years. Females constituted 55.2% of the population. Obesity (96.1%), hypertension (71.6%), and retinopathy (13.7%) were the most commonly reported comorbidities. The study showed a significant reduction in body weight, BMI, HbA1c, hemoglobin, mean corpuscular volume (MCV), serum LDL-C, and triglyceride concentrations after three months of using dulaglutide (p<0.001). Conclusion Our study results confirm the positive effect of the GLP-1RA (dulaglutide) on the lipid profile of diabetic patients with dyslipidemia uncontrolled by statins.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanObservational studyEfficacy outcome
In patients with diabetes and dyslipidemia uncontrolled by statins, dulaglutide use was linked to lower LDL-C than before treatment.
In plain wordsIn patients with diabetes and uncontrolled blood lipids, dulaglutide use was linked to lower LDL cholesterol than before treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseSerum LDL-C
Study
n = 102
Comparator
Before dulaglutide
Analysis
Primary
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · three monthsAs given in this study (human).
Source sentences
Summary
The study showed a significant reduction in body weight, BMI, HbA1c, hemoglobin, mean corpuscular volume (MCV), serum LDL-C, and triglyceride concentrations after three months of using dulaglutide (p<0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
Methods Data were collected from the medical records of male and female diabetic patients with dyslipidemia (uncontrolled by statins) who were administered to the diabetic center of King Salman Bin Abdulaziz Hospital in Riyadh, Saudi Arabia, and received GLP-1RA (dulaglutide) from June 2023 to August 2023.
Summary · context
The primary endpoint was the change in triglycerides and LDL-C levels after three months of using dulaglutide, and the secondary endpoints included the change in body weight, BMI, and HbA1c%.
Summary · context
Results The study included 102 patients with a median (interquartile range (IQR)) age of 59 (14) years.
Show in the study text Report a problemFND-3918850406
02HumanObservational studyEfficacy outcome
In patients with diabetes and dyslipidemia uncontrolled by statins, dulaglutide use was linked to lower triglycerides than before treatment.
In plain wordsIn patients with diabetes and uncontrolled blood lipids, dulaglutide use was linked to lower triglycerides than before treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseTriglycerides
Study
n = 102
Comparator
Before dulaglutide
Analysis
Primary
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · three monthsAs given in this study (human).
Source sentences
Summary
The study showed a significant reduction in body weight, BMI, HbA1c, hemoglobin, mean corpuscular volume (MCV), serum LDL-C, and triglyceride concentrations after three months of using dulaglutide (p<0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
Methods Data were collected from the medical records of male and female diabetic patients with dyslipidemia (uncontrolled by statins) who were administered to the diabetic center of King Salman Bin Abdulaziz Hospital in Riyadh, Saudi Arabia, and received GLP-1RA (dulaglutide) from June 2023 to August 2023.
Summary · context
The primary endpoint was the change in triglycerides and LDL-C levels after three months of using dulaglutide, and the secondary endpoints included the change in body weight, BMI, and HbA1c%.
Summary · context
Results The study included 102 patients with a median (interquartile range (IQR)) age of 59 (14) years.
Show in the study text Report a problemFND-3918850407
03HumanObservational studyEfficacy outcome
In patients with diabetes and dyslipidemia uncontrolled by statins, dulaglutide use was linked to lower weight than before treatment.
In plain wordsIn patients with diabetes and uncontrolled blood lipids, dulaglutide use was linked to lower weight than before treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBody weight
Study
n = 102
Comparator
Before dulaglutide
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · three monthsAs given in this study (human).
Source sentences
Summary
The study showed a significant reduction in body weight, BMI, HbA1c, hemoglobin, mean corpuscular volume (MCV), serum LDL-C, and triglyceride concentrations after three months of using dulaglutide (p<0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
Methods Data were collected from the medical records of male and female diabetic patients with dyslipidemia (uncontrolled by statins) who were administered to the diabetic center of King Salman Bin Abdulaziz Hospital in Riyadh, Saudi Arabia, and received GLP-1RA (dulaglutide) from June 2023 to August 2023.
Summary · context
The primary endpoint was the change in triglycerides and LDL-C levels after three months of using dulaglutide, and the secondary endpoints included the change in body weight, BMI, and HbA1c%.
Summary · context
Results The study included 102 patients with a median (interquartile range (IQR)) age of 59 (14) years.
Show in the study text Report a problemFND-3918850401
04HumanObservational studyEfficacy outcome
In patients with diabetes and dyslipidemia uncontrolled by statins, dulaglutide use was linked to lower BMI than before treatment.
In plain wordsIn patients with diabetes and uncontrolled blood lipids, dulaglutide use was linked to lower BMI than before treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBMI
Study
n = 102
Comparator
Before dulaglutide
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · three monthsAs given in this study (human).
Source sentences
Summary
The study showed a significant reduction in body weight, BMI, HbA1c, hemoglobin, mean corpuscular volume (MCV), serum LDL-C, and triglyceride concentrations after three months of using dulaglutide (p<0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
Methods Data were collected from the medical records of male and female diabetic patients with dyslipidemia (uncontrolled by statins) who were administered to the diabetic center of King Salman Bin Abdulaziz Hospital in Riyadh, Saudi Arabia, and received GLP-1RA (dulaglutide) from June 2023 to August 2023.
Summary · context
The primary endpoint was the change in triglycerides and LDL-C levels after three months of using dulaglutide, and the secondary endpoints included the change in body weight, BMI, and HbA1c%.
Summary · context
Results The study included 102 patients with a median (interquartile range (IQR)) age of 59 (14) years.
Show in the study text Report a problemFND-3918850402
05HumanObservational studyEfficacy outcome
In patients with diabetes and dyslipidemia uncontrolled by statins, dulaglutide use was linked to lower HbA1c than before treatment.
In plain wordsIn patients with diabetes and uncontrolled blood lipids, dulaglutide use was linked to lower long-term blood sugar than before treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c
Study
n = 102
Comparator
Before dulaglutide
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · three monthsAs given in this study (human).
Source sentences
Summary
The study showed a significant reduction in body weight, BMI, HbA1c, hemoglobin, mean corpuscular volume (MCV), serum LDL-C, and triglyceride concentrations after three months of using dulaglutide (p<0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
Methods Data were collected from the medical records of male and female diabetic patients with dyslipidemia (uncontrolled by statins) who were administered to the diabetic center of King Salman Bin Abdulaziz Hospital in Riyadh, Saudi Arabia, and received GLP-1RA (dulaglutide) from June 2023 to August 2023.
Summary · context
The primary endpoint was the change in triglycerides and LDL-C levels after three months of using dulaglutide, and the secondary endpoints included the change in body weight, BMI, and HbA1c%.
Summary · context
Results The study included 102 patients with a median (interquartile range (IQR)) age of 59 (14) years.
Show in the study text Report a problemFND-3918850403
06HumanObservational studyEfficacy outcome
In patients with diabetes and dyslipidemia uncontrolled by statins, dulaglutide use was linked to lower hemoglobin than before treatment.
In plain wordsIn patients with diabetes and uncontrolled blood lipids, dulaglutide use was linked to lower hemoglobin than before treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHemoglobin
Study
n = 102
Comparator
Before dulaglutide
Outcome group
Overall treatment effect · Whole body
Studied dose
Dose not stated · three monthsAs given in this study (human).
Source sentences
Summary
The study showed a significant reduction in body weight, BMI, HbA1c, hemoglobin, mean corpuscular volume (MCV), serum LDL-C, and triglyceride concentrations after three months of using dulaglutide (p<0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
Methods Data were collected from the medical records of male and female diabetic patients with dyslipidemia (uncontrolled by statins) who were administered to the diabetic center of King Salman Bin Abdulaziz Hospital in Riyadh, Saudi Arabia, and received GLP-1RA (dulaglutide) from June 2023 to August 2023.
Summary · context
The primary endpoint was the change in triglycerides and LDL-C levels after three months of using dulaglutide, and the secondary endpoints included the change in body weight, BMI, and HbA1c%.
Summary · context
Results The study included 102 patients with a median (interquartile range (IQR)) age of 59 (14) years.
Show in the study text Report a problemFND-3918850404
07HumanObservational studyEfficacy outcome
In patients with diabetes and dyslipidemia uncontrolled by statins, dulaglutide use was linked to lower mean corpuscular volume than before treatment.
In plain wordsIn patients with diabetes and uncontrolled blood lipids, dulaglutide use was linked to smaller average red blood cell volume than before treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseMean corpuscular volume
Study
n = 102
Comparator
Before dulaglutide
Outcome group
Overall treatment effect · Whole body
Studied dose
Dose not stated · three monthsAs given in this study (human).
Source sentences
Summary
The study showed a significant reduction in body weight, BMI, HbA1c, hemoglobin, mean corpuscular volume (MCV), serum LDL-C, and triglyceride concentrations after three months of using dulaglutide (p<0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
Methods Data were collected from the medical records of male and female diabetic patients with dyslipidemia (uncontrolled by statins) who were administered to the diabetic center of King Salman Bin Abdulaziz Hospital in Riyadh, Saudi Arabia, and received GLP-1RA (dulaglutide) from June 2023 to August 2023.
Summary · context
The primary endpoint was the change in triglycerides and LDL-C levels after three months of using dulaglutide, and the secondary endpoints included the change in body weight, BMI, and HbA1c%.
Summary · context
Results The study included 102 patients with a median (interquartile range (IQR)) age of 59 (14) years.
Show in the study text Report a problemFND-3918850405

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.